Critical Review: Windtree Therapeutics (WINT) vs. Anavex Life Sciences (AVXL)

Windtree Therapeutics (OTCMKTS: WINT) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and recommmendations for Windtree Therapeutics and Anavex Life Sciences, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Windtree Therapeutics 0 1 0 0 2.00
Anavex Life Sciences 0 0 2 0 3.00

Anavex Life Sciences has a consensus price target of $15.00, indicating a potential upside of 318.99%. Given Anavex Life Sciences’ stronger consensus rating and higher possible upside, analysts clearly believe Anavex Life Sciences is more favorable than Windtree Therapeutics.

Insider and Institutional Ownership

0.3% of Windtree Therapeutics shares are held by institutional investors. Comparatively, 23.9% of Anavex Life Sciences shares are held by institutional investors. 3.5% of Windtree Therapeutics shares are held by insiders. Comparatively, 11.6% of Anavex Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Risk and Volatility

Windtree Therapeutics has a beta of 1.76, suggesting that its share price is 76% more volatile than the S&P 500. Comparatively, Anavex Life Sciences has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500.

Earnings and Valuation

This table compares Windtree Therapeutics and Anavex Life Sciences’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Windtree Therapeutics $2.04 million 7.90 -$39.49 million ($3.59) -0.07
Anavex Life Sciences N/A N/A -$14.73 million ($0.39) -9.18

Anavex Life Sciences has lower revenue, but higher earnings than Windtree Therapeutics. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Windtree Therapeutics and Anavex Life Sciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Windtree Therapeutics -1,205.47% N/A -345.52%
Anavex Life Sciences N/A -95.68% -84.88%

Summary

Anavex Life Sciences beats Windtree Therapeutics on 9 of the 12 factors compared between the two stocks.

About Windtree Therapeutics

Windtree Therapeutics, Inc., formerly Discovery Laboratories, Inc., is a biotechnology company. The Company is focused on developing KL4 surfactant therapies for respiratory diseases and other potential applications. The Company operates through the research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products segment. The Company’s technology platform includes a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant, and drug delivery technologies being developed to enable non-invasive administration of aerosolized KL4 surfactant. The Company’s core development program, AEROSURF (lucinactant for inhalation), is focused on improving the management of respiratory distress syndrome (RDS) in premature infants, a respiratory condition that can result in long-term respiratory problems, developmental delay and death.

About Anavex Life Sciences

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases. The Company’s SIGMACEPTOR Discovery Platform produced small molecule drug candidates with unique modes of action. Sigma receptors may be targets for therapeutics to combat many human diseases, including Alzheimer’s disease. When bound by the appropriate ligands, sigma receptors influence the functioning of multiple biochemical signals that are involved in the pathogenesis (origin or development) of disease.

Receive News & Ratings for Windtree Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Windtree Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply